The world's first triple hormone receptor agonist — showing up to 24% weight loss
GIPGLP-1Glucagon
⚡ Why the hype? Retatrutide adds glucagon receptor activation to the dual-agonist formula. This means enhanced fat burning (thermogenesis) on top of appetite suppression. Phase 2 trials showed the highest weight loss ever recorded for an obesity medication.
The NEJM Phase 2 trial (Jastreboff et al., 2023) enrolled adults with obesity. At 48 weeks:
12 mg dose: 24.2% mean weight loss
8 mg dose: 22.8% mean weight loss
4 mg dose: 17.5% mean weight loss
Placebo: 2.1% weight loss
For context, semaglutide (Wegovy) achieved ~15% and tirzepatide (Mounjaro) achieved ~21% in their trials.
📋 Retatrutide Titration Schedule
Based on clinical trial protocols. Always start low and titrate slowly.
Week
Dose
Notes
1-4
0.5 mg
Starting dose, GI adjustment
5-8
1 mg
First increase
9-12
2 mg
Moderate dose
13-16
4 mg
Effective dose for many
17-24
8 mg
Higher efficacy dose
25+
12 mg
Maximum studied dose
⚠️ Slow Escalation Matters: The clinical trials used "slow escalation" protocols. Rushing to high doses increases GI side effects (nausea, vomiting, diarrhea). Most side effects were mild-moderate and decreased over time.
Proven mechanism (same as semaglutide/tirzepatide)
Glucagon — The Game Changer
Increases energy expenditure (you burn more calories at rest)
Promotes fat burning through lipolysis
Hepatic effects — helps regulate liver fat
This is what makes retatrutide potentially more effective than dual agonists
💡 The Theory: GLP-1 and GIP reduce hunger. Glucagon increases calorie burn. You eat less AND burn more. That's why the weight loss numbers are higher than previous medications.
⚖️ Retatrutide vs. Tirzepatide vs. Semaglutide
Feature
Semaglutide
Tirzepatide
Retatrutide
Mechanism
GLP-1
GIP + GLP-1
GIP + GLP-1 + Glucagon
Weight Loss (trials)
~15%
~21%
~24%
Max Dose
2.4 mg
15 mg
12 mg (studied)
FDA Status
✅ Approved
✅ Approved
⏳ Phase 3
Brand Names
Ozempic, Wegovy
Mounjaro, Zepbound
TBD (Eli Lilly)
Energy Expenditure
Minimal
Some
Significant ↑
🔮 Current Status & Timeline
Developer: Eli Lilly (same company as tirzepatide/Mounjaro)
Indications Being Studied: Obesity, Type 2 Diabetes, MASLD (fatty liver)
📈 The Pattern: Every major weight loss breakthrough follows the same path: bodybuilding → Hollywood → mainstream. GH in the 80s. TRT in the 90s. GLP-1s in the 2020s. Retatrutide is next. — This was called out by @hubaboratory on X.
⚠️ Side Effects & Considerations
Common Side Effects (from Phase 2)
GI symptoms: Nausea, diarrhea, vomiting, constipation (most common)
Usually mild-to-moderate severity
Decreased with slower titration
Tended to improve over time
Important Considerations
Not yet FDA approved — research compound only
Long-term safety data still being collected
Contraindicated with personal/family history of MTC (medullary thyroid carcinoma)
Not for use during pregnancy
⚠️ Research Only: Retatrutide is not FDA approved. Any use is strictly for research purposes. Consult with a healthcare provider before using any peptide. Quality control and purity vary significantly between sources.
📚 Clinical References
Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389:514-526. PubMed
Rosenstock J et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." Lancet. 2023;402:529-544. PubMed
Sanyal AJ et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease." Nat Med. 2024;30:2037-2048. PubMed